Citations

Showing 10 of 108152 citations.

Association Between Graft Choice and 6-Year Outcomes of Revision Anterior Cruciate Ligament Reconstruction in the MARS Cohort
Group, MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Pennings, Jacquelyn S. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Stuart, Michael J., Albright, John P., Amendola, Annunziato , Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Campbell, John D. , Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Johnson, Timothy S. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Svoboda, Steven J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Campbell, John D., David, Tal S. , Giffin, J. Robert , Johnson, David C., Jones, Morgan H. , McAllister, David R. , Owens, Brett D. , Shea, Kevin G. , Sherman, Orrin H. , Williams, James S.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2021 | Volume: 49 | Issue: 10 | Pages: 2589-2598

10.1177/03635465211027170 | PMID 34260326 Get It

Background: Although graft choice may be limited in the revision setting based on previously used grafts, most surgeons believe that graft choice for anterior cruciate ligament (ACL) reconstruction is an important factor related to outcome. Hypothesis: In the ACL revision setting, there would be no difference between autograft and allograft in rerupture rate and patient-reported outcomes (PROs) at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who had revision surgery were identified and prospectively enrolled in this cohort study by 83 surgeons over 52 sites. Data collected included baseline characteristics, surgical technique and pathology, and a series of validated PRO measures. Patients were followed up at 6 years and asked to complete the identical set of PRO instruments. Incidence of additional surgery and reoperation because of graft failure were also recorded. Multivariable regression models were used to determine the predictors (risk factors) of PROs, graft rerupture, and reoperation at 6 years after revision surgery. Results: A total of 1234 patients including 716 (58%) men were enrolled. A total of 325 (26%) underwent revision using a bone-patellar tendon-bone (BTB) autograft; 251 (20%), soft tissue autograft; 289 (23%), BTB allograft; 302 (25%), soft tissue allograft; and 67 (5%), other graft. Questionnaires and telephone follow-up for subsequent surgery information were obtained for 809 (66%) patients, while telephone follow-up was only obtained for an additional 128 patients for the total follow-up on 949 (77%) patients. Graft choice was a significant predictor of 6-year Marx Activity Rating Scale scores ( P = .024). Specifically, patients who received a BTB autograft for revision reconstruction had higher activity levels than did patients who received a BTB allograft (odds ratio [OR], 1.92; 95% CI, 1.25-2.94). Graft rerupture was reported in 5.8% (55/949) of patients by their 6-year follow-up: 3.5% (16/455) of patients with autografts and 8.4% (37/441) of patients with allografts. Use of a BTB autograft for revision resulted in patients being 4.2 times less likely to sustain a subsequent graft rupture than if a BTB allograft were utilized ( P = .011; 95% CI, 1.56-11.27). No significant differences were found in graft rerupture rates between BTB autograft and soft tissue autografts ( P = .87) or between BTB autografts and soft tissue allografts ( P = .36). Use of an autograft was found to be a significant predictor of having fewer reoperations within 6 years compared with using an allograft ( P = .010; OR, 0.56; 95% CI, 0.36-0.87). Conclusion: BTB and soft tissue autografts had a decreased risk in graft rerupture compared with BTB allografts. BTB autografts were associated with higher activity level than were BTB allografts at 6 years after revision reconstruction. Surgeons and patients should consider this information when choosing a graft for revision ACL reconstruction.
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment
Spitzweg, Christine , Nelson, Peter J. , Wagner, Ernst , Bartenstein, Peter , Weber, Wolfgang , Weber, Wolfgang A , Wagner, Ernst , Schwaiger, Markus , Morris, J C

Mayo Clinic

Endocrine-Related Cancer | July 14, 2021 | Volume: 28 | Issue: 10 | Pages: T193-T213

10.1530/erc-21-0177 | PMID 34259647 Get It

Cloning of the sodium iodide symporter (NIS) 25 years ago has opened an exciting chapter in molecular thyroidology with the characterization of NIS as one of the most powerful theranostic genes and the development of a promising gene therapy strategy based on image-guided selective NIS gene transfer in non-thyroidal tumors followed by application of 131 I or alternative radionuclides, such as 188 Re and 211 At. Over the past two decades, significant progress has been made in the development of the NIS gene therapy concept, from local NIS gene delivery towards promising new applications in disseminated disease, in particular through the use of oncolytic viruses, non-viral polyplexes, and genetically engineered MSCs as highly effective, highly selective and flexible gene delivery vehicles. In addition to allowing the robust therapeutic application of radioiodine in non-thyroid cancer settings, these studies have also been able to take advantage of NIS as a sensitive reporter gene that allows temporal and spatial monitoring of vector biodistribution, replication, and elimination – critically important issues for preclinical development and clinical translation.
Sex-Specific Differences in Glioblastoma
Carrano, Anna , Whaley, Juan José Juárez‐Vignon , Incontri‐Abraham, Diego , Ibarra, Antonio , Guerrero‐Cazares, Hugo , Juarez, Juan Jose , Incontri, Diego , Guerrero-Cazares, Hugo

Mayo Clinic

Cells | July 14, 2021 | Volume: 10 | Issue: 7 | Pages: 1783

10.3390/cells10071783 | PMID 34359952 Get It

Sex differences have been well identified in many brain tumors. Even though glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has the worst outcome, well-established differences between men and women are limited to incidence and outcome. Little is known about sex differences in GBM at the disease phenotype and genetical/molecular level. This review focuses on a deep understanding of the pathophysiology of GBM, including hormones, metabolic pathways, the immune system, and molecular changes, along with differences between men and women and how these dimorphisms affect disease outcome. The information analyzed in this review shows a greater incidence and worse outcome in male patients with GBM compared with female patients. We highlight the protective role of estrogen and the upregulation of androgen receptors and testosterone having detrimental effects on GBM. Moreover, hormones and the immune system work in synergy to directly affect the GBM microenvironment. Genetic and molecular differences have also recently been identified. Specific genes and molecular pathways, either upregulated or downregulated depending on sex, could potentially directly dictate GBM outcome differences. It appears that sexual dimorphism in GBM affects patient outcome and requires an individualized approach to management considering the sex of the patient, especially in relation to differences at the molecular level.
Expansion of the Genotypic and Phenotypic Spectrum of WASF1-Related Neurodevelopmental Disorder
Srivastava, Siddharth , Macke, Erica L. , Swanson, Lindsay C., Coulter, David L., Klee, Eric W. , Mullegama, Sureni V. , Xie, Yili, Lanpher, Brendan C. , Skraban, Cara , Villard, Laurent , Milh, Mathieu , Cohen, Julie S. , Villard, Laurent , Bedoukian, Emma C. , Leppert, Mary L. O’Connor

Mayo Clinic

Brain Sciences | July 14, 2021 | Volume: 11 | Issue: 7 | Pages: 931

10.3390/brainsci11070931 | PMID 34356165 Get It

In humans, de novo truncating variants in WASF1 (Wiskott–Aldrich syndrome protein family member 1) have been linked to presentations of moderate-to-profound intellectual disability (ID), autistic features, and epilepsy. Apart from one case series, there is limited information on the phenotypic spectrum and genetic landscape of WASF1-related neurodevelopmental disorder (NDD). In this report, we describe detailed clinical characteristics of six individuals with WASF1-related NDD. We demonstrate a broader spectrum of neurodevelopmental impairment including more mildly affected individuals. Further, we report new variant types, including a copy number variant (CNV), resulting in the partial deletion of WASF1 in monozygotic twins, and three missense variants, two of which alter the same residue, p.W161. This report adds further evidence that de novo variants in WASF1 cause an autosomal dominant NDD.
A systematic review on outcome reporting in randomised controlled trials assessing treatment interventions in pregnant women with pregestational diabetes
Kgosidialwa, Oratile , Bogdanet, Delia , Egan, Aoife M. , Newman, Christine , O’Shea, Paula , Biesty, Linda , McDonagh, C, O'Shea, C, Devane, Declan , Dunne, Fidelma , Kgosidialwa, O , Bogdanet, D , Egan, A M , O'Shea, Paula M , Dunne, Fidelma P , Newman, Christine

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 14, 2021 | Volume: 128 | Issue: 12 | Pages: 1894-1904

10.1111/1471-0528.16842 | PMID 34258852 Get It

BackgroundPregestational diabetes mellitus (PGDM) is associated with adverse pregnancy outcomes. Studies assessing interventions to improve maternal and infant outcomes have increased exponentially over recent years. Several outcomes in this field of maternal diabetes are rare, making it difficult to synthesise evidence.ObjectivesTo collect outcomes reported in studies assessing treatment interventions in pregnant women with PGDM.Search strategyCENTRAL, Web of Science, Medline, CINAHL, Embase and ClinicalTrials.gov from their inception until 27 January 2020.Selection criteriaAny randomised controlled trial assessing treatment interventions in pregnant women with PGDM reported in English.Data collection and analysisTwo independent reviewers assessed the suitability of articles and retrieved the data. Outcomes extracted from the literature were broadly categorised into maternal, fetal/infant or other outcomes by the study advisory group.Main resultsSixty‐seven of the 1475 studies identified fulfilled the inclusion criteria. The median number of outcomes reported per study was 15 (range 1–46). The majority of studies were from North America and Europe. Insulin and metformin were the most commonly investigated pharmacological interventions. Glucose monitoring was the most assessed technological intervention. In all, 131 unique outcomes were extracted: maternal (n = 69), fetal/infant (n = 61) and other (n = 1).ConclusionsOutcome reporting in treatment interventions trials of pregnant women with PGDM is varied, making it difficult to synthesise evidence, especially for rare outcomes. Systems are needed to standardise outcome reporting in future clinical trials and so facilitate evidence synthesis in this area of maternal diabetes.RegistrationThe systematic review was registered prospectively with the International Prospective Register of Systematic Reviews (PROSPERO) database (Registration number CRD42020173549).Tweetable abstractOutcome reporting is heterogeneous in intervention trials of pregnant women with diabetes existing before pregnancy.
MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update
Diaz, Teresa A., Benson, Benjamin , Clinkenbeard, Alexander, Long, Jeremiah R. , Yano, Motoyo , Kawashima, Akira

Mayo Clinic

American Journal of Roentgenology | July 14, 2021 | Volume: 218 | Issue: 1 | Pages: 88-99

10.2214/ajr.21.26278 | PMID 34259037 Get It

Pronated Grip View With Wrist Deviation: A Pilot Study on the Effect on Ulnocarpal Relationships
Logli, Anthony L. , Schueler, Beth A. , Littrell, Laurel A. , Kakar, Sanjeev , Kakar, Sanjeev

Mayo Clinic

HAND | July 14, 2021 | Volume: 18 | Issue: 3 | Pages: 501-508

10.1177/15589447211028928 | PMID 34259079 Get It

Background We hypothesize that different positions of the wrist in the coronal plane makes the carpus susceptible to ulnar impaction. Methods We prospectively enrolled 10 adult volunteers and obtained fluoroscopic images of each wrist in 12 different positions using a standardized protocol. Distances from the ulna to the lunate (UL) and ulna to the triquetrum (UT) were digitally measured as was the portion of the lunate surface area that was uncovered (LUR) with wrist deviation. Results A wrist position of Pronation, Neutral Deviation, and Grip (P-ND-G) significantly shortened the ulnocarpal distance when compared to a position of Neutral Rotation, Neutral Deviation, and No Grip (NR-ND-NG). Radial deviation during pronation and gripping (Pronated, Radial Deviation, Gripping [P-RD-G]) resulted in the lowest mean UL distance (1.2 mm). UT distance was minimized by a position of ulnar deviation during a pronated grip (Pronated, Ulnar Deviation, Gripping [P-UD-G]) (3.1 mm). The lunate becomes more uncovered with radial deviation. Conclusion Radial deviation minimizes the UL distance while ulnar deviation minimizes the UT distance during a wrist position of pronation and gripping. Further, there is more proximal lunate surface area uncoverage during all positions of radial deviation compared to ulnar deviation.
Artificial intelligence in inflammatory bowel disease endoscopy: current landscape and the road ahead
Sundaram, Suneha , Choden, Tenzin , Mattar, Mark , Desai, Madhav , Desai, Sanjal , Desai, Madhav , Desai, Sanjal H.

Mayo Clinic

Therapeutic Advances in Gastrointestinal Endoscopy | July 14, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/26317745211017809 | PMID 34345816 Get It

Inflammatory bowel disease is a complex chronic inflammatory disorder with challenges in diagnosis, choosing appropriate therapy, determining individual responsiveness, and prediction of future disease course to guide appropriate management. Artificial intelligence has been examined in the field of inflammatory bowel disease endoscopy with promising data in different domains of inflammatory bowel disease, including diagnosis, assessment of mucosal activity, and prediction of recurrence and complications. Artificial intelligence use during endoscopy could be a step toward precision medicine in inflammatory bowel disease care pathways. We reviewed available data on use of artificial intelligence for diagnosis of inflammatory bowel disease, grading of severity, prediction of recurrence, and dysplasia detection. We examined the potential role of artificial intelligence enhanced endoscopy in various aspects of inflammatory bowel disease care and future perspectives in this review.
Distinct phenotypes of hospitalized patients with hyperkalemia by machine learning consensus clustering and associated mortality risks
Thongprayoon, Charat , Kattah, Andrea G. , Keddis, Mira T. , Pattharanitima, Pattharawin , Vallabhajosyula, Saraschandra , Nissaisorakarn, Voravech , Erickson, Stephen B., Cheungpasitporn, Wisit , Thongprayoon, Charat , Keddis, Mira , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Pattharanitima, Pattharawin , Mao, Michael A. , Dillon, John , Garovic, Vesna D.

Mayo Clinic

QJM: An International Journal of Medicine | July 14, 2021 | Volume: 115 | Issue: 7 | Pages: 442-449

10.1093/qjmed/hcab194 | PMID 34270780 Get It

Summary Background Hospitalized patients with hyperkalemia are heterogeneous, and cluster approaches may identify specific homogenous groups. This study aimed to cluster patients with hyperkalemia on admission using unsupervised machine learning (ML) consensus clustering approach, and to compare characteristics and outcomes among these distinct clusters. Methods Consensus cluster analysis was performed in 5133 hospitalized adult patients with admission hyperkalemia, based on available clinical and laboratory data. The standardized mean difference was used to identify each cluster’s key clinical features. The association of hyperkalemia clusters with hospital and 1-year mortality was assessed using logistic and Cox proportional hazard regression. Results Three distinct clusters of hyperkalemia patients were identified using consensus cluster analysis: 1661 (32%) in cluster 1, 2455 (48%) in cluster 2 and 1017 (20%) in cluster 3. Cluster 1 was mainly characterized by older age, higher serum chloride and acute kidney injury (AKI), but lower estimated glomerular filtration rate (eGFR), serum bicarbonate and hemoglobin. Cluster 2 was mainly characterized by higher eGFR, serum bicarbonate and hemoglobin, but lower comorbidity burden, serum potassium and AKI. Cluster 3 was mainly characterized by higher comorbidity burden, particularly diabetes and end-stage kidney disease, AKI, serum potassium, anion gap, but lower eGFR, serum sodium, chloride and bicarbonate. Hospital and 1-year mortality risk was significantly different among the three identified clusters, with highest mortality in cluster 3, followed by cluster 1 and then cluster 2. Conclusion In a heterogeneous cohort of hyperkalemia patients, three distinct clusters were identified using unsupervised ML. These three clusters had different clinical characteristics and outcomes.
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
Nadauld, Lincoln , McDonnell, Charles H. , Beer, Tomasz M. , Liu, Minetta C. , Klein, Eric A. , Hudnut, Andrew , Whittington, Richard, Oxnard, Geoffrey R. , Lipson, Jafi A. , Lopatin, Margarita , Shaknovich, Rita , Chung, Karen , Fung, Eric T. , Marinac, Catherine R. , Lipson, Jafi , Chung, Karen C , Marinac, Catherine R , Klein, Eric A , Beer, Tomasz M , Taylor, Bruce , Schrag, Deborah

Mayo Clinic

Cancers | July 13, 2021 | Volume: 13 | Issue: 14 | Pages: 3501

10.3390/cancers13143501 | PMID 34298717 Get It

To examine the extent of the evaluation required to achieve diagnostic resolution and the test performance characteristics of a targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test, ~6200 participants ≥50 years with (cohort A) or without (cohort B) ≥1 of 3 additional specific cancer risk factors will be enrolled in PATHFINDER (NCT04241796), a prospective, longitudinal, interventional, multi-center study. Plasma cfDNA from blood samples will be analyzed to detect abnormally methylated DNA associated with cancer (i.e., cancer “signal”) and a cancer signal origin (i.e., tissue of origin). Participants with a “signal detected” will undergo further diagnostic evaluation per guiding physician discretion; those with a “signal not detected” will be advised to continue guideline-recommended screening. The primary objective will be to assess the number and types of subsequent diagnostic tests needed for diagnostic resolution. Based on microsimulations (using estimates of cancer incidence and dwell times) of the typical risk profiles of anticipated participants, the median (95% CI) number of participants with a “signal detected” result is expected to be 106 (87–128). Subsequent diagnostic evaluation is expected to detect 52 (39–67) cancers. The positive predictive value of the MCED test is expected to be 49% (39–58%). PATHFINDER will evaluate the integration of a cfDNA-based MCED test into existing clinical cancer diagnostic pathways. The study design of PATHFINDER is described here.